Table 2.
Differences in median values of TAbs-RBD (U/ml) and NAbs-RBD (%) SARS-CoV-2 spike antibodies after the first and second dose of BNT162b2 vaccine regarding demographic and clinical characteristics in cystic fibrosis patients (n = 33).
| After 1st dose |
After 2nd dose |
||||
|---|---|---|---|---|---|
| n (%) | TAbs-RBD (U/ml) | NAbs-RBD (%) | TAbs-RBD (U/ml) | NAbs-RBD (%) | |
|
Gender |
Male 15 (45.5) |
280.70 (1736.70) |
80.20 (20.80) |
3381.00 (2776.00) |
97.30 (1.60) |
| Female 18 (54.5) |
214.70 (164.10) |
79.20 (15.60) |
3642.50 (2322.00) |
97.35 (0.40) |
|
| P-value | .526 | .845 | .532 | .421 | |
|
Local Adverse Events |
No 1st dose: 25 (75.8) 2nd dose: 24 (72.7) |
231.00 (1401.45) |
81.60 (15.40) |
3785.00 (3271.00) |
97.30 (1.00) |
| Yes 1st dose: 8 (24.2) 2nd dose: 9 (27.3) |
166.55 (855.74) |
69.80 (11.50) |
2881.00 (1544.00) |
97.30 (0.60) |
|
| P-value | .380 | .089 | .486 | .677 | |
|
Systemic Adverse Events |
No 1st dose: 29 (87.9) 2nd dose: 24 (72.7) |
223.25 (1253.95) |
79.60 (15.60) |
3388.50 (2497.00) |
97.30 (0.95) |
| Yes 1st dose: 4 (12.1) 2nd dose: 9 (27.3) |
140.91 (218.75) |
75.30 (29.60) |
4445.00 (5319.00) |
97.30 (0.90) |
|
| P-value | .254 | .811 | .437 | .706 | |
|
Pancreatic Status |
Pancreatic insufficiency 28 (84.8) |
214.70 (1350.50) |
79.20 (16.75) |
3388.50 (2430.50) |
97.30 (0.95) |
| Pancreatic sufficiency 5 (15.2) |
244.00 (324.80) |
80.20 (15.20) |
3681.00 (2018.00) |
97.60 (0.50) |
|
| P-value | >.999 | .903 | .643 | .478 | |
|
CFRD |
No 29 (87.9) |
212.65 (1269.05) |
78.80 (16.00) |
3396.00 (2311.00) |
97.30 (1.20) |
| Yes 4 (12.1) |
231.00 (106.86) |
88.80 (9.80) |
4987.00 (6813.50) |
97.20 (0.40) |
|
| P-value | .763 | .133 | .730 | .690 | |
|
CFTR Modulators |
No 19 (57.6) |
231.80 (1679.30) |
76.70 (19.60) |
3917.00 (2443.00) |
97.40 (1.20) |
| Yes 14 (42.4) |
197.60 (201.94) |
81.95 (14.10) |
3127.00 (2629.00) |
97.30 (0.80) |
|
| P-value | .195 | .529 | .627 | .900 | |
|
CFTR genotype§ |
F508del/F508del 15 (45.5) |
184.30 (214.14) |
79.60 (18.30) |
3268.00 (2224.00) |
97.30 (1.00) |
| F508del/other 13 (39.4) |
230.20 (1678.90) |
76.70 (17.70) |
4708.00 (4825.00) |
97.50 (0.60) |
|
| Other 5 (15.2) |
244.00 (76.70) |
81.60 (5.20) |
3381.00 (1246.00) |
97.20 (0.30) |
|
| P-value | .324 | .955 | .718 | .412 | |
|
Chronic PA |
No 19 (57.6) |
268.45 (1129.20) |
81.50 (17.60) |
3889.00 (3817.00) |
97.30 (1.30) |
| Yes 14 (42.4) |
153.25 (201.94) |
75.25 (16.80) |
3324.50 (2486.00) |
97.30 (0.60) |
|
| P-value | .111 | .274 | .362 | .971 | |
Abbreviations: TAbs-RBD; Total antibodies against Receptor Binding Domain of SARS-CoV-2 spike protein, NAbs-RBD; Neutralizing antibodies (%), CFRD; Cystic fibrosis-related diabetes, PA; Pseudomonas aeruginosa. Values refer to median (interquartile range) and P-value of Mann-Whitney U test or §Kruskal-Wallis H test. Statistically significant values are marked in bold.